查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070379

膽管癌藥物市場規模、佔有率、成長、全球產業分析、區域洞察及2026-2034年預測。

Cholangiocarcinoma Drugs Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

膽管癌藥物市場的成長要素

由於臨床上對罕見和進行性膽道癌的關注度日益提高，全球膽管癌藥物市場正經歷顯著成長。膽管癌是一種起源於膽管的癌症，傳統上化療一直是其主要治療方法。然而，精準醫療、生物標記檢測、免疫療法和標靶治療的進步正在極大地改變膽管癌的治療方式。基因組分析的日益普及使醫生能夠識別攜帶FGFR2融合基因、IDH1突變、HER2表達以及其他分子突變的患者，從而實現更個人化的治療方案，並改善臨床療效。

市場規模及預測

2025年全球膽管癌藥物市場規模為12.9億美元。預計到2026年，該市場將達到14.9億美元，到2034年將進一步擴大至37.8億美元，預測期（2026-2034年）的複合年成長率為12.34%。

由於先進的醫療保健基礎設施、生物標記檢測的廣泛應用以及新核准治療方法的快速推廣，預計到 2025 年，北美將引領全球市場，佔據 39.53% 的市場佔有率。

市場趨勢

生物標記標靶治療的應用日益廣泛

最重要的市場趨勢之一是基於生物標記的治療策略的日益普及。分子譜分析使醫療專業人員能夠識別特定的基因突變，例如FGFR2融合、IDH1突變和HER2陽性腫瘤，從而可以使用高度標靶的治療方法，而不是僅依賴傳統的化療。

lilaglatinib、pemigatinib 和 zanidatamab 等藥物的持續研發，凸顯了該行業向個人化醫療和精準腫瘤學的轉變。

市場促進因素

精準醫療的廣泛應用

精準醫療是膽管癌藥物市場的主要成長要素。基因組檢測在臨床實踐中的日益普及，使得醫生能夠根據每個腫瘤的個別特徵選擇治療方法。這種方法在改善治療效果的同時，也滿足了對創新標靶治療的需求。

製藥公司增加對 FGFR 抑制劑、IDH1 抑制劑、HER2標靶治療和免疫療法的投資，進一步推動了市場成長。

市場限制因素

患者數量少

儘管治療方法不斷進步，膽管癌仍然是一種罕見癌症。患者數量相對較少限制了許多治療方法的商業性潛力，也為臨床試驗的患者招募帶來了挑戰。

由於招募受試者困難而導致某些藥物研發計畫中止，這表明這種疾病的罕見性會對臨床開發和商業性可行性產生怎樣的影響。

市場機遇

由於獲得新監管機構的批准，市場規模擴大

創新治療方法的法規核准為市場創造了巨大的成長機會。標靶治療和免疫療法的獲批，拓展了傳統化療以外的治療選擇。

針對 HER2 陽性、FGFR2 驅動和 IDH1 突變膽管癌的治療方法獲得批准，開闢了新的治療領域，並鼓勵對精準腫瘤學進行進一步投資。

市場挑戰

高昂的醫療費用

標靶治療和特效抗癌藥物的高成本仍然是一大挑戰。由於這些治療方法大多針對由生物標記定義的小眾患者群體，因此其價格往往遠高於傳統治療方法。

對成本效益的擔憂、保險報銷方面的挑戰以及醫療預算緊張等問題可能會限制這些治療方法的普及，尤其是在開發中國家市場。

區域分析

北美洲

北美仍然是最大的區域市場，預計到 2025 年將達到 5.1 億美元。該地區受益於先進的診斷能力、廣泛的生物標記檢測以及創新治療方法的早期應用。

預計到 2026 年，美國市場規模將達到約 5.4 億美元，約佔全球整體銷售額的 36.12%。

歐洲

預計到 2026 年，歐洲將以 10.78% 的複合年成長率成長，達到 3.7 億美元，這主要得益於發病率上升和精準醫療覆蓋範圍擴大。

亞太地區

預計到 2026 年，亞太地區的癌症治療市場規模將達到 4 億美元，主要得益於大量患者、日益增強的癌症意識以及對癌症研究投入的增加。

拉丁美洲、中東和非洲

由於醫療基礎設施的改善和癌症治療機會的增加，預計這些地區將經歷適度成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 按主要區域分類的膽管癌盛行率
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）
  • 主要國家和地區的監管趨勢
  • 2025年各地區主要創業公司

第5章：2021-2034年全球膽管癌藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：按療法分類。
    • 化療
    • 免疫療法
    • 標靶治療
    • 其他
  • 市場分析、洞察與預測：按藥物類別分類
    • 抗代謝物
    • 鉑化合物
    • PD-L1抑制劑
    • FGFR抑制劑
    • IDH1抑制劑
    • HER2標靶治療
    • PD-1抑制劑
    • 其他
  • 市場分析、洞察與預測：按疾病適應症分類
    • 肝內膽管癌
    • 肝門部膽管癌
    • 遠端膽管癌
    • 進行性/復發性膽管癌
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 非專利的
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美膽管癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲膽管癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區膽管癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲膽管癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲膽管癌藥物市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Incyte
    • Innovent Biologics
    • Servier
    • Taiho Pharmaceutical
    • Jazz Pharmaceuticals
    • AstraZeneca
    • Merck & Co., Inc.,
    • Relay Therapeutics
    • Elevar Therapeutics
    • Eisai Inc.
Product Code: FBI115942

Growth Factors of cholangiocarcinoma drugs Market

The global cholangiocarcinoma drugs market is witnessing significant growth due to increasing clinical focus on rare and aggressive biliary tract cancers. Cholangiocarcinoma, a cancer originating in the bile ducts, has historically been treated with chemotherapy; however, advancements in precision medicine, biomarker testing, immunotherapy, and targeted therapies are transforming the treatment landscape. Growing adoption of genomic profiling is enabling physicians to identify patients with FGFR2 fusions, IDH1 mutations, HER2 expression, and other molecular alterations, leading to more personalized treatment approaches and improved clinical outcomes.

Market Size and Forecast

The global cholangiocarcinoma drugs market was valued at USD 1.29 billion in 2025. The market is projected to reach USD 1.49 billion in 2026 and further expand to USD 3.78 billion by 2034, registering a CAGR of 12.34% during the forecast period (2026-2034).

North America dominated the global market with a 39.53% market share in 2025, supported by advanced healthcare infrastructure, strong adoption of biomarker testing, and rapid uptake of newly approved therapies.

Market Trends

Increasing Adoption of Biomarker-Driven Targeted Therapies

One of the most significant trends in the market is the growing use of biomarker-based treatment strategies. Molecular profiling enables healthcare providers to identify specific genetic alterations such as FGFR2 fusions, IDH1 mutations, and HER2-positive tumors, allowing the use of highly targeted therapies instead of traditional chemotherapy alone.

The growing development of drugs such as lirafugratinib, pemigatinib, and zanidatamab highlights the industry's shift toward personalized medicine and precision oncology.

Market Drivers

Rising Adoption of Precision Medicine

Precision medicine has become a major growth driver in the cholangiocarcinoma drugs market. Increasing integration of genomic testing into clinical practice allows physicians to select therapies based on individual tumor characteristics. This approach improves treatment effectiveness while supporting demand for innovative targeted therapies.

Growing investments by pharmaceutical companies in FGFR inhibitors, IDH1 inhibitors, HER2-targeted therapies, and immunotherapies are further strengthening market growth.

Market Restraints

Small Patient Population

Despite advancements in treatment, cholangiocarcinoma remains a rare cancer. The relatively small patient pool limits the commercial potential of many therapies and creates challenges in patient recruitment for clinical trials.

The withdrawal of certain drug programs due to enrollment difficulties demonstrates how the rarity of the disease can affect both clinical development and commercial viability.

Market Opportunities

Expansion Through New Regulatory Approvals

Regulatory approvals for innovative therapies are creating substantial growth opportunities in the market. New approvals for targeted therapies and immunotherapies are expanding treatment options beyond conventional chemotherapy.

The approval of therapies targeting HER2-positive, FGFR2-driven, and IDH1-mutated cholangiocarcinoma is opening new treatment segments and encouraging greater investment in precision oncology.

Market Challenges

High Treatment Costs

The high cost of targeted therapies and specialty oncology drugs remains a significant challenge. Since many of these treatments are designed for small biomarker-defined populations, their prices are often substantially higher than conventional therapies.

Affordability concerns, reimbursement challenges, and healthcare budget pressures may restrict broader adoption, particularly in developing markets.

Segmentation Analysis

By Therapy

The Chemotherapy segment dominated the market in 2025 due to its widespread use as a first-line treatment for advanced and unresectable cholangiocarcinoma. However, the Immunotherapy segment is expected to witness the fastest growth with a CAGR of 26.01% during the forecast period.

By Drug Class

The Antimetabolites segment held the largest market share in 2025, primarily due to the extensive use of gemcitabine-based treatment regimens. The PD-L1 Inhibitors segment is anticipated to grow rapidly at a CAGR of 41.88%.

By Disease Indication

Advanced/Recurrent Cholangiocarcinoma accounted for the largest share in 2025 because most patients are diagnosed at advanced stages when systemic drug treatment becomes necessary.

By Age Group

The Adult Segment dominated the market owing to the significantly higher prevalence of cholangiocarcinoma among adults and elderly populations.

By Type

Branded Drugs held the largest market share because most innovative therapies remain under patent protection and face limited generic competition.

By Route of Administration

The Parenteral Segment dominated the market due to the extensive use of intravenous chemotherapy, immunotherapy, and antibody-based treatments.

By Distribution Channel

Hospital Pharmacies represented the leading distribution channel, supported by the specialist oncology care required for cholangiocarcinoma treatment.

Regional Analysis

North America

North America remained the largest regional market, reaching USD 0.51 billion in 2025. The region benefits from advanced diagnostic capabilities, widespread biomarker testing, and early adoption of innovative therapies.

The U.S. market is estimated to reach approximately USD 0.54 billion in 2026, accounting for around 36.12% of global revenue.

Europe

Europe is projected to grow at a CAGR of 10.78% and reach USD 0.37 billion in 2026, driven by increasing incidence rates and expanding access to precision medicine.

Asia Pacific

Asia Pacific is expected to reach USD 0.40 billion in 2026, supported by a large patient population, increasing awareness, and growing investment in oncology research.

Latin America and Middle East & Africa

These regions are anticipated to experience moderate growth due to improving healthcare infrastructure and increasing access to cancer therapies.

Competitive Landscape

The cholangiocarcinoma drugs market is highly consolidated, with major companies focusing on research collaborations, product development, and regulatory approvals to strengthen their market positions.

Key players include:

  • Incyte
  • Innovent Biologics
  • Servier
  • Taiho Pharmaceutical
  • Jazz Pharmaceuticals
  • AstraZeneca
  • Merck & Co.
  • Relay Therapeutics
  • Elevar Therapeutics

These companies are actively investing in targeted therapies, immunotherapies, strategic partnerships, and global expansion initiatives.

Conclusion

The global cholangiocarcinoma drugs market is entering a phase of strong expansion, driven by the increasing adoption of precision medicine and biomarker-guided therapies. The market is projected to grow from USD 1.29 billion in 2025 to USD 1.49 billion in 2026, ultimately reaching USD 3.78 billion by 2034 at a CAGR of 12.34%. Rising use of genomic profiling, growing approvals of targeted therapies, and expanding immunotherapy applications will continue to reshape treatment standards. Although challenges such as high treatment costs and a limited patient population remain, continuous innovation and regulatory support are expected to create substantial growth opportunities throughout the forecast period.

Segmentation By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Region

By Therapy * Chemotherapy

  • Immunotherapy
  • Targeted Therapy
  • Others

By Drug Class * Antimetabolites

  • Platinum Compounds
  • PD-L1 Inhibitors
  • FGFR Inhibitors
  • IDH1 Inhibitors
  • HER2-Directed Therapies
  • PD-1 Inhibitors
  • Others

By Disease Indication * Intrahepatic Cholangiocarcinoma

  • Perihilar Cholangiocarcinoma
  • Distal Cholangiocarcinoma
  • Advanced/Recurrent Cholangiocarcinoma
  • Others

By Age Group * Pediatric

  • Adult

By Type * Branded

  • Generic

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region * North America (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy, Drug Class, Disease Indication, Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cholangiocarcinoma, By Key Region
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Regulatory Scenario, By Key Countries/Regions
  • 4.5. Key Start Up, By Key Regions, 2025

5. Global Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy
    • 5.1.1. Chemotherapy
    • 5.1.2. Immunotherapy
    • 5.1.3. Targeted Therapy
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Antimetabolites
    • 5.2.2. Platinum Compounds
    • 5.2.3. PD-L1 Inhibitors
    • 5.2.4. FGFR Inhibitors
    • 5.2.5. IDH1 Inhibitors
    • 5.2.6. HER2-Directed Therapies
    • 5.2.7. PD-1 Inhibitors
    • 5.2.8. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Intrahepatic Cholangiocarcinoma
    • 5.3.2. Perihilar Cholangiocarcinoma
    • 5.3.3. Distal Cholangiocarcinoma
    • 5.3.4. Advanced / Recurrent Cholangiocarcinoma
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatric
    • 5.4.2. Adult
  • 5.5. Market Analysis, Insights and Forecast - By Type
    • 5.5.1. Branded
    • 5.5.2. Generic
  • 5.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.6.1. Oral
    • 5.6.2. Parenteral
  • 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.7.1. Hospital Pharmacies
    • 5.7.2. Drug Stores & Retail Pharmacies
    • 5.7.3. Online Pharmacies
  • 5.8. Market Analysis, Insights and Forecast - Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. Asia Pacific
    • 5.8.4. Latin America
    • 5.8.5. Middle East & Africa

6. North America Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy
    • 6.1.1. Chemotherapy
    • 6.1.2. Immunotherapy
    • 6.1.3. Targeted Therapy
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Antimetabolites
    • 6.2.2. Platinum Compounds
    • 6.2.3. PD-L1 Inhibitors
    • 6.2.4. FGFR Inhibitors
    • 6.2.5. IDH1 Inhibitors
    • 6.2.6. HER2-Directed Therapies
    • 6.2.7. PD-1 Inhibitors
    • 6.2.8. Others
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Intrahepatic Cholangiocarcinoma
    • 6.3.2. Perihilar Cholangiocarcinoma
    • 6.3.3. Distal Cholangiocarcinoma
    • 6.3.4. Advanced / Recurrent Cholangiocarcinoma
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatric
    • 6.4.2. Adult
  • 6.5. Market Analysis, Insights and Forecast - By Type
    • 6.5.1. Branded
    • 6.5.2. Generic
  • 6.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.6.1. Oral
    • 6.6.2. Parenteral
  • 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.7.1. Hospital Pharmacies
    • 6.7.2. Drug Stores & Retail Pharmacies
    • 6.7.3. Online Pharmacies
  • 6.8. Market Analysis, Insights and Forecast - By Country
    • 6.8.1. U.S.
    • 6.8.2. Canada

7. Europe Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy
    • 7.1.1. Chemotherapy
    • 7.1.2. Immunotherapy
    • 7.1.3. Targeted Therapy
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Antimetabolites
    • 7.2.2. Platinum Compounds
    • 7.2.3. PD-L1 Inhibitors
    • 7.2.4. FGFR Inhibitors
    • 7.2.5. IDH1 Inhibitors
    • 7.2.6. HER2-Directed Therapies
    • 7.2.7. PD-1 Inhibitors
    • 7.2.8. Others
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Intrahepatic Cholangiocarcinoma
    • 7.3.2. Perihilar Cholangiocarcinoma
    • 7.3.3. Distal Cholangiocarcinoma
    • 7.3.4. Advanced / Recurrent Cholangiocarcinoma
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatric
    • 7.4.2. Adult
  • 7.5. Market Analysis, Insights and Forecast - By Type
    • 7.5.1. Branded
    • 7.5.2. Generic
  • 7.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.6.1. Oral
    • 7.6.2. Parenteral
  • 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.7.1. Hospital Pharmacies
    • 7.7.2. Drug Stores & Retail Pharmacies
    • 7.7.3. Online Pharmacies
  • 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.8.1. U.K.
    • 7.8.2. Germany
    • 7.8.3. France
    • 7.8.4. Italy
    • 7.8.5. Spain
    • 7.8.6. Scandinavia
    • 7.8.7. Rest of Europe

8. Asia Pacific Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy
    • 8.1.1. Chemotherapy
    • 8.1.2. Immunotherapy
    • 8.1.3. Targeted Therapy
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Antimetabolites
    • 8.2.2. Platinum Compounds
    • 8.2.3. PD-L1 Inhibitors
    • 8.2.4. FGFR Inhibitors
    • 8.2.5. IDH1 Inhibitors
    • 8.2.6. HER2-Directed Therapies
    • 8.2.7. PD-1 Inhibitors
    • 8.2.8. Others
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Intrahepatic Cholangiocarcinoma
    • 8.3.2. Perihilar Cholangiocarcinoma
    • 8.3.3. Distal Cholangiocarcinoma
    • 8.3.4. Advanced / Recurrent Cholangiocarcinoma
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatric
    • 8.4.2. Adult
  • 8.5. Market Analysis, Insights and Forecast - By Type
    • 8.5.1. Branded
    • 8.5.2. Generic
  • 8.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.6.1. Oral
    • 8.6.2. Parenteral
  • 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.7.1. Hospital Pharmacies
    • 8.7.2. Drug Stores & Retail Pharmacies
    • 8.7.3. Online Pharmacies
  • 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.8.1. China
    • 8.8.2. Japan
    • 8.8.3. India
    • 8.8.4. Southeast Asia
    • 8.8.5. Australia
    • 8.8.6. Rest of Asia Pacific

9. Latin America Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy
    • 9.1.1. Chemotherapy
    • 9.1.2. Immunotherapy
    • 9.1.3. Targeted Therapy
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Antimetabolites
    • 9.2.2. Platinum Compounds
    • 9.2.3. PD-L1 Inhibitors
    • 9.2.4. FGFR Inhibitors
    • 9.2.5. IDH1 Inhibitors
    • 9.2.6. HER2-Directed Therapies
    • 9.2.7. PD-1 Inhibitors
    • 9.2.8. Others
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Intrahepatic Cholangiocarcinoma
    • 9.3.2. Perihilar Cholangiocarcinoma
    • 9.3.3. Distal Cholangiocarcinoma
    • 9.3.4. Advanced / Recurrent Cholangiocarcinoma
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatric
    • 9.4.2. Adult
  • 9.5. Market Analysis, Insights and Forecast - By Type
    • 9.5.1. Branded
    • 9.5.2. Generic
  • 9.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.6.1. Oral
    • 9.6.2. Parenteral
  • 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Drug Stores & Retail Pharmacies
    • 9.7.3. Online Pharmacies
  • 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.8.1. Brazil
    • 9.8.2. Mexico
    • 9.8.3. Rest of Latin America

10. Middle East & Africa Cholangiocarcinoma Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy
    • 10.1.1. Chemotherapy
    • 10.1.2. Immunotherapy
    • 10.1.3. Targeted Therapy
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Antimetabolites
    • 10.2.2. Platinum Compounds
    • 10.2.3. PD-L1 Inhibitors
    • 10.2.4. FGFR Inhibitors
    • 10.2.5. IDH1 Inhibitors
    • 10.2.6. HER2-Directed Therapies
    • 10.2.7. PD-1 Inhibitors
    • 10.2.8. Others
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Intrahepatic Cholangiocarcinoma
    • 10.3.2. Perihilar Cholangiocarcinoma
    • 10.3.3. Distal Cholangiocarcinoma
    • 10.3.4. Advanced / Recurrent Cholangiocarcinoma
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatric
    • 10.4.2. Adult
  • 10.5. Market Analysis, Insights and Forecast - By Type
    • 10.5.1. Branded
    • 10.5.2. Generic
  • 10.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.6.1. Oral
    • 10.6.2. Parenteral
  • 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Drug Stores & Retail Pharmacies
    • 10.7.3. Online Pharmacies
  • 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.8.1. GCC
    • 10.8.2. South Africa
    • 10.8.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Incyte
    • 11.2.2. Innovent Biologics
    • 11.2.3. Servier
    • 11.2.4. Taiho Pharmaceutical
    • 11.2.5. Jazz Pharmaceuticals
    • 11.2.6. AstraZeneca
    • 11.2.7. Merck & Co., Inc.,
    • 11.2.8. Relay Therapeutics
    • 11.2.9. Elevar Therapeutics
    • 11.2.10. Eisai Inc.

List of Tables

  • Figure 1: Global Cholangiocarcinoma Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cholangiocarcinoma Drugs Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 3: Global Cholangiocarcinoma Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 4: Global Cholangiocarcinoma Drugs Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Cholangiocarcinoma Drugs Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 6: Global Cholangiocarcinoma Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 7: Global Cholangiocarcinoma Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 8: Global Cholangiocarcinoma Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 9: Global Cholangiocarcinoma Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 10: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 11: North America Cholangiocarcinoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 12: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 13: North America Cholangiocarcinoma Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 14: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Disease Indication 2025 & 2034
  • Figure 15: North America Cholangiocarcinoma Drugs Market Value Share (%), by Disease Indication 2025
  • Figure 16: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 17: North America Cholangiocarcinoma Drugs Market Value Share (%), by Age Group, 2025
  • Figure 18: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 19: North America Cholangiocarcinoma Drugs Market Value Share (%), by Type, 2025
  • Figure 20: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 21: North America Cholangiocarcinoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 22: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 23: North America Cholangiocarcinoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 24: North America Cholangiocarcinoma Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 25: North America Cholangiocarcinoma Drugs Market Value Share (%), by Country, 2025
  • Figure 26: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 27: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 28: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 29: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 30: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Disease Indication 2025 & 2034
  • Figure 31: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Disease Indication 2025
  • Figure 32: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 33: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Age Group, 2025
  • Figure 34: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 35: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Type, 2025
  • Figure 36: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 37: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 38: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 39: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 40: Europe Cholangiocarcinoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 41: Europe Cholangiocarcinoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 42: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 43: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 44: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 46: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Disease Indication 2025 & 2034
  • Figure 47: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Disease Indication 2025
  • Figure 48: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 49: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Age Group, 2025
  • Figure 50: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 51: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Type, 2025
  • Figure 52: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 53: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 54: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 55: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 56: Asia Pacific Cholangiocarcinoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 57: Asia Pacific Cholangiocarcinoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 58: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 59: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 60: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 61: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 62: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Disease Indication 2025 & 2034
  • Figure 63: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Disease Indication 2025
  • Figure 64: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 65: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Age Group, 2025
  • Figure 66: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 67: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Type, 2025
  • Figure 68: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 69: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 70: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 71: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 72: Latin America Cholangiocarcinoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 73: Latin America Cholangiocarcinoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 74: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 75: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Therapy, 2025
  • Figure 76: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 77: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 78: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Disease Indication 2025 & 2034
  • Figure 79: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Disease Indication 2025
  • Figure 80: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 81: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Age Group, 2025
  • Figure 82: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Type, 2025 & 2034
  • Figure 83: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Type, 2025
  • Figure 84: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 85: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 86: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 87: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 88: Middle East & Africa Cholangiocarcinoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 89: Middle East & Africa Cholangiocarcinoma Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 90: Global Cholangiocarcinoma Drugs Market Share (%), by Company, 2025